[1] |
Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 2015, 65(2): 87-108.
|
[2] |
Sinclair P,Singh A,Riaz AA, et al. An unsolved conundrum: the ideal follow-up strategy after curative surgery for colorectal cancer. Gastrointestinal endoscopy, 2012, 75(5): 1072-1079.
|
[3] |
Becker G,Galandi D,Blum HE. Malignant ascites: systematic review and guideline for treatment. European journal of cancer, 2006, 42(5): 589-597.
|
[4] |
Montero E,Miguel J,Lopez-Alvarez J. Care of patients with ascites. The New England journal of medicine, 1994, 330(25): 1828.
|
[5] |
Liu Y,Luan L,Wang X. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and therapy, 2015, 8: 1061-1068.
|
[6] |
Hurwitz HI,Fehrenbacher L,Hainsworth JD, et al. Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. Journal of Clinical Oncology, 2005, 23(15): 3502-3508.
|
[7] |
Adam RA,Adam YG. Malignant ascites: past, present, and future. Journal of the American College of Surgeons, 2004, 198(6): 999-1011.
|
[8] |
Saada E,Follana P,Peyrade F, et al. Pathogenesis and management of refractory malignant ascites. Bulletin du cancer, 2011, 98(6): 679-687.
|
[9] |
Yabushita H,Shimazu M,Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncology Reports, 2003, 10(1): 89-95.
|
[10] |
Atanackovic D,Cao Y,Kim J-W, et al. The local cytokine and chemokine milieu within malignant effusions. Tumor Biology, 2008, 29(2): 93-104.
|
[11] |
Cavazzoni E,Bugiantella W,Graziosi L, et al. Malignant ascites: pathophysiology and treatment. International journal of clinical oncology, 2013, 18(1): 1-9.
|
[12] |
Smolle E,Taucher V,Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer research, 2014, 34(4): 1553-1561.
|
[13] |
Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul, 1995, 35: 293-301.
|
[14] |
Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine, 1971, 285(21): 1182-1186.
|
[15] |
Numnum TM,Rocconi RP,Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology, 2006, 102(3): 425-428.
|
[16] |
el-Shami K,Griffiths E,Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. The oncologist, 2007, 12(5): 518-523.
|
[17] |
Pichelmayer O,Zielinski C,Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. New England Journal of Medicine, 2005, 353(7): 740-741.
|